[Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer]

ObjectiveTo observe the clinical effect of cinobuf ac ini injection in treating moderate and advanced primary liver cancer (PLC). WT HZMethodsOne hundred patients with moderate and advanced PLC were rando mly divided into cino-treated group (50 patients) and control group (50 patient s). The quality of life, tumor size, some changes of laboratory tests, and survi val time were observed. ResultsThe progressive rate of cino-trea ted group (18%) was lower than that of the control group (32%). The quality of l ife of the cino-treated group (80%) was better than that of the control group ( 72%), but witbout statistical significance. The survival rate of 12 months of t he cino-treated group (30%) was higher than that of the control group (18%). Th e patients’ liver function such as serum total bilirubin and ALT decreased obvi ously in the cino-treated group while increased a lot in the control group. The level of AFP increased after treatment with statistical significance in the con trol group while there was no statistical significance in the cino-treated grou p. ConclusionCinobufacini injection can not only inhibit the proli feration of cancer, but also protect liver function, improve quality of life and prolong survival time.